Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

NCT05318963 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped The collaborators decided to terminate this study.

Conditions

B-cell Lymphoma Recurrent
B-cell Lymphoma Refractory

Interventions

BIOLOGICAL: LCAR-AIO cells product

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

[object Object]